Tools chosen: polymarket_direct claude_news claude_news gdelt_news polymarket_related kalshi_related earnings_data wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a binary regulatory-approval question with a ~2-year horizon; the key drivers are the INTerpath-001 Phase 3 readout timing, whether Moderna/Merck pursue accelerated approval (and whether FDA would accept a surrogate endpoint like RFS), and whether a BLA has been or will be filed early enough for a decision before Dec 31, 2027. The Polymarket price is the primary anchor, supplemented by news on trial timelines and company regulatory guidance.

# Current state The Phase 3 INTerpath-001 trial met its primary (RFS) and key secondary (DMFS) endpoints, announced Aug 19, 2026 — a major positive catalyst — but as of the latest research, Moderna/Merck have NOT yet filed a BLA/sBLA; they are only "engaging with regulators" and plan to present full data at a medical conference first. Resolution requires actual FDA approval (not just positive trial data or filing) by Dec 31, 2027. # Timeline of key events - 2023 — FDA grants Breakthrough Therapy Designation to intismeran autogene + KEYTRUDA combo, based on Phase 2b data (confirmed, Targeted Oncology). - 2024 — Moderna/Merck hold preliminary regulatory discussions seeking approval on Phase 2 data; FDA gives discouraging feedback (reported, BioSpace). - 2026-06-02/03 — 5-year Phase 2 follow-up data show sustained ~49% reduction in recurrence/death risk (confirmed, Yahoo/Fox News/Targeted Oncology). - 2026-08-19 — Phase 3 INTerpath-001 interim analysis: primary (RFS) and key secondary (DMFS) endpoints met; first positive Phase 3 for an individualized neoantigen/mRNA cancer therapy; Moderna stock +93-177%, Merck +7% (confirmed, Merck.com, BioSpace, FierceBiotech, Al Jazeera). - Post-Aug 2026 (ongoing) — Companies plan to present full data at an international medical meeting and "engage regulators" on filing; no BLA submission or PDUFA date confirmed yet (reported, multiple outlets). OS data remains immature; trial continues for long-term follow-up. # Event Will the FDA approve intismeran autogene (mRNA-4157/V940, Moderna/Merck) for any indication by Dec 31, 2027? # Outcomes to forecast - Yes (FDA approval granted by Dec 31, 2027) - No (not approved by deadline) # Kalshi market anchor No kalshi_direct price was returned in this research pull (data gap). The only related Kalshi markets found (FDA approval of VERVE-102: 50%; Type 1 diabetes cure: 36%; MDMA for PTSD: 56%) are not directly comparable but show FDA-approval markets often price well below simple headline optimism. **Treat this as a missing anchor — the closest available proxy is Polymarket's 69% YES.** # Sub-question answers 1. **Polymarket price/history** — Current YES = 69%, flat 7d/30d, only 1 data point, $17k volume (Polymarket_direct). Thin data — likely reflects post-Phase-3-readout optimism, not a mature time series. 2. **Phase 3 readout date/guidance** — Readout occurred Aug 19, 2026 (interim analysis); RFS and DMFS met; OS immature and trial continues (Merck.com, FierceBiotech). No specific "primary completion" date beyond this interim readout is disclosed. 3. **BLA submission / expedited pathway** — No BLA filed as of latest reporting (Aug 2026+); companies "plan to engage regulators" and present full data at a medical meeting first. Breakthrough Therapy Designation already granted (2023). Moderna's President said a positive interim readout "would make the case for an accelerated review," but no confirmed accelerated-approval agreement yet (FierceBiotech). 4. **FDA review timelines** — Priority review: ~6 months from filing; standard: ~10 months (Wikipedia/Priority Review). Given readout Aug 2026, a filing needs to occur roughly by Q1 2027 (accelerated) or earlier for standard, to permit approval by Dec 2027. 5. **Negative signals** — 2024 FDA gave discouraging feedback on Phase 2-based filing attempt (BioSpace) — a real precedent for regulatory caution. No current clinical hold, trial delay, or Moderna deprioritization; Moderna's 2026 guidance reiterates growth/pipeline investment, oncology program appears prioritized (FierceBiotech/Nasdaq). 6. **Historical base rate** — No individualized neoantigen/personalized mRNA cancer therapy has previously reached FDA approval; this would be first-in-class, adding regulatory-novelty risk beyond typical timelines (Wikipedia/Intismeran autogene page). # Key facts (high-confidence, factual) 1. [Merck.com/BioSpace] Phase 3 INTerpath-001 met RFS + DMFS endpoints, announced Aug 19, 2026. 2. [Targeted Oncology] FDA granted Breakthrough Therapy Designation in 2023. 3. [BioSpace] FDA gave discouraging feedback in 2024 on a Phase-2-based filing approach. 4. [Multiple] As of latest reporting, no BLA has been filed; companies are only "engaging regulators." 5. [Wikipedia] Standard FDA review = ~10 months; priority review = ~6 months from filing. 6. [Merck.com] OS endpoint remains immature; trial continues. # Cross-market signals - Kalshi related: FDA approval markets for other drugs price 36–56% (VERVE-102, T1D cure, MDMA) — general reference point for FDA-approval uncertainty, not this drug. - Polymarket: 69% YES, thin/stale data (1 data point, $17k volume) — likely overweights recent stock-surge sentiment rather than filing/review-timeline mechanics. - Sportsbook implied: N/A. # Analyst opinions and speculation - Moderna's Stephen Hoge suggested positive Phase 3 data supports case for accelerated review (FierceBiotech) — speculative, not confirmed by FDA. - Model (code_execution Monte Carlo): base-case ~32.5% (range 25–38%), driven primarily by tight timeline between Aug 2026 readout and Dec 2027 deadline, not by clinical-success uncertainty. # Directional lean per outcome - **Yes**: Strong positive Phase 3 data, prior Breakthrough Designation, sponsor incentive for speed, precedent of oncology accelerated approvals. - **No**: No BLA filed yet as of latest data; FDA previously skeptical (2024); OS data still immature; first-in-class product with no approval precedent; compressed timeline (readout Aug 2026 → deadline Dec 2027) is historically tight even under priority review. # Gaps / unknowns - No kalshi_direct price captured — critical gap for anchoring. - No confirmed BLA filing date or PDUFA date. - Unknown whether FDA will grant accelerated/priority review for this specific filing. - Unknown full data presentation date/conference. # Calibration anchors - Polymarket YES (proxy anchor): 69%. - Quant model fair-value estimate: ~25–38% (central ~33%). - Comparable FDA-approval markets on Kalshi: 36–56% range. - Base rate for first-in-class oncology approval within ~16 months of positive Phase 3 interim readout (with BTD, no filing yet): historically below 50%, given typical BLA-to-approval cycles of 10–14 months from actual filing (not from readout).

1. Both forecasters anchor mostly on the 25-38% quant model and the 36-56% Kalshi-comparable range, but neither fully explains why they land above that range (35% and 45%) rather than within or below it — Forecast 2 in particular admits the model says 25-38% yet picks 45%, a ~7-20pt unexplained upward deviation that isn't justified by new evidence, just "not as low as." 2. Neither forecaster addresses the concrete mechanical bottleneck in detail: even if BLA filing happens by, say, Q1 2027, CMC/manufacturing review for an individualized, patient-specific neoantigen therapy (unique per-patient production) is a novel regulatory challenge with no precedent — this could add review time beyond a normal priority-review drug, yet both treat priority review timelines as if standard biologics precedent applies. 3. Both forecasters underweight the specific 2024 discouraging FDA feedback as a base-rate signal — this wasn't generic caution but a direct rejection of an earlier filing attempt on this same drug, suggesting the agency has specific concerns (likely OS immaturity or manufacturing) that a Phase 3 RFS/DMFS win alone may not resolve before 2027. 4. Neither forecaster gives a probability estimate for the sub-event "does a BLA even get filed by mid-2027" separately from "does FDA approve after filing" — collapsing these into one holistic number obscures that even a high-40s/50s conditional approval probability post-filing could be swamped by a filing delay (e.g., waiting for the "international medical meeting" presentation, full OS maturity, etc.), which historically can push timelines by 6-12+ months. 5. Both treat Polymarket's 69% as an inflated, low-quality anchor to fade, but neither considers it might also reflect informed insider/analyst sentiment on likely accelerated-approval mechanics (e.g., RTOR, rolling submission) — dismissing it entirely without exploring the possibility of a rolling review that started before the Aug 2026 readout is a potential blind spot. 6. Neither forecast explicitly addresses the asymmetry that "approval by Dec 2027" is a compound event requiring both (a) successful clinical outcome — largely already de-risked by the Phase 3 win — and (b) a very specific administrative timeline, yet both converge in the 35-45% range without decomposing how much probability mass is lost purely to timeline risk versus approval-decision risk, which the brief's Monte Carlo explicitly separates ("driven primarily by tight timeline... not by clinical-success uncertainty").

33% (50% confidence)

Yes: 33% No: 67%

Resolution requires an actual FDA approval by Dec 31, 2027, and the binding constraint is administrative timing, not clinical success. Decomposing: P(BLA/sBLA filed early enough — roughly by Q1–Q2 2027, after the planned full-data conference presentation) is maybe ~55–60%, and P(approval by Dec 2027 | timely filing) is perhaps ~55–60% given filing-to-acceptance lag, priority review of ~6 months, and unprecedented CMC/manufacturing review for a patient-specific individualized neoantigen product — yielding roughly one-third overall. The devil's advocate is right that both forecasters drifted above the ~25–38% quant range without new justification, and that the 2024 FDA discouragement was drug-specific (likely OS-maturity/manufacturing concerns) rather than generic caution; immature OS data remains a live obstacle. Polymarket's 69% is a single thin data point ($17k) reflecting post-readout headline euphoria and is not a reliable anchor, though rolling review/RTOR under Breakthrough designation is a genuine upside path that keeps me from going below ~30%. I therefore land near the model's base case at 33% Yes.

Total pipeline time: 230.1s